Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone in cirrhotic ICU patients with vasopressor-dependent shock and suspected sepsis
2010-024273-38Phase 3Terminated
- Sponsor
- UZ Leuven
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of hydrocortisone in Cirrhosis, septic shock and Shock (2 arms), sponsored by UZ Leuven. Primary endpoint: 28-day mortality. Started Sep 2013; status: terminated.
02
Drugs
hydrocortisone
03
Conditions
Cirrhosisseptic shockShock
Beyond the preview
Go deeper on 2010-024273-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024273-38.